Zacks Research upgraded shares of Hemab Therapeutics (NASDAQ:COAG – Free Report) to a hold rating in a research report released on Wednesday,Zacks.com reports.
Several other analysts also recently issued reports on COAG. Jefferies Financial Group started coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $39.00 price target for the company. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $36.00 price target for the company. Evercore started coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $50.00 price target for the company. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, Wedbush started coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $42.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $41.75.
Check Out Our Latest Stock Analysis on Hemab Therapeutics
Hemab Therapeutics Stock Performance
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last posted its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.
Insider Transactions at Hemab Therapeutics
In other news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the acquisition, the director directly owned 6,149,096 shares of the company’s stock, valued at $110,683,728. The trade was a 77.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have acquired 2,902,872 shares of company stock worth $53,769,784.
About Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Read More
- Five stocks we like better than Hemab Therapeutics
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
